ESR1 and neoplasm: Normal-weight patients with a nuclear InsR−/ER+ tumor, which constituted two thirds of the patients, had the lowest risk for recurrence compared to all other nuclear InsR/ER combinations (HRadj 0.50, 95% CI: 0.25–0.97; Figure 2B).